Gilead Sciences Inc has acquired privately-held EpiTherapeutics ApS for $65 million in cash. The Denmark-based company has a library of small molecules that inhibit the epigenetic regulation of gene transcription which has uses in combating cancer. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
